BioPorto: Mission and Vision
BioPorto will constantly seek to select new diagnostic biomarker targets from the marketed antibody portfolio that have clinical relevance, potential for a large market in routine diagnostics and for patent protection and by this selection achieve as large a share of the routine diagnostic market as possible.
Share information
Investor Relations
To BioPorto, openness and transparency are essential in maintaining good relations with investors.
The purpose of Investor Relations and this website is to ensure that correct and adequate information about BioPorto is made available to all interested parties simultaneously, regularly and consistently.
Investor news
11: BioPorto’s NGAL patent approved for issue in Europe
July 30 2008
10: BioPorto launches Rat NGAL ELISA Kit
June 27 2008
09: New diagnostic application of the APC-PCI test
June 23 2008
